4 – 6 July, 2018
ENYO Pharma is proud to announce that a Poster made with Inventiva and Rachel Nechushtai from Hebrew University of Jerusalem will be presented at the 54th edition of the International Conference on Medicinal Chemistry (RICT 2018) in Strasbourg, France on July 4-6, 2018.
RICT will focus on “Interfacing Chemical Biology and Drug Discovery”. The 3-day international congress offers the opportunity to ENYO Pharma to present a novel virus-inspired approach to discover first-in-class preclinical assets for a wide range of therapeutic areas.
4-7 June, 2018
“The BIO International Convention is hosted by the Biotechnology Innovation Organization, which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products”.
17-18 May, 2018
“MATWIN organises in Bordeaux on May 17th and 18th 2018 the 4th edition of its European Business Convention entirely dedicated to open innovation, collaborative research and technology transfer: MEET2WIN.
Organized around one-to-one meetings and bringing together all the parties involved in oncology innovation, MEET2WIN offers the opportunity to meet representatives of big pharma companies, biotechs, start-up, project leaders researchers, clinicians, TTO’s, investors etc. to increase R&D private/public partnerships”.
10 – 11 May, 2018
“Genesis Drug Discovery (GDD) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange that will give all the participants the opportunity to share their experiences, foster collaborations across industry and academia and evaluate emerging technologies across the globe.
Genesis Drug Discovery (GDD) provides a platform to promote international exchanges for drug discovery, and to accelerate the cooperation for new drug research and development in the global market.
April 11-15, 2018
ENYO Pharma is proud to announce that its Poster has been selected to be presented at EASL International Liver Congress in Paris on April 11-15th. The company team will present its latest Hepatitis B studies and data about its EYP001 compound (FXR agonist) developed for chronic hepatitis B patients. The annual Congress, which aim at presenting the latest topics in liver research, will be a great opportunity for the company as more than 10,000 delegates and 250 media representatives from all over the world will participate.